Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Metronomic Capecitabine in Refractory HNC/ESCC (McCrest-2)
NCT04510818Phase 1Unknown
- Sponsor
- Ruijin Hospital
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camrelizumab in head and neck cancer (HNC) and Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Ruijin Hospital. Primary endpoint: Rate of adverse events at 48 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
head and neck cancer (HNC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04510818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510818.